EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment and Validation of a Transdermal Drug Delivery System for the Anti-Depressant Drug Citalopram Hydrobromide

Yi-Yang Sun, Ya-Jing Ni, Run-Jia Wang, Zi-Cheng Qin, Zhao Liu, Li-Hui Xiao, Yan-Qiang Liu iD

Molecules · 07.02.2024 · 29 (4) · 767

DOI: 10.3390/molecules29040767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 07.02.2024. Verfasst von Yi-Yang Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Nankai University, Tianjin 300071, China. Hauptthemen laut MEDLINE: Skin Absorption, Citalopram. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Tianjin City, Fundamental Research Funds for the Central Universities of Nankai University, University–Enterprise Cooperation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To enhance the bioavailability and antihypertensive effect of the anti-depressant drug citalopram hydrobromide (CTH) we developed a sustained-release transdermal delivery system containing CTH. A transdermal diffusion meter was first used to determine the optimal formulation of the CTH transdermal drug delivery system (TDDS). Then, based on the determined formulation, a sustained-release patch was prepared; its physical characteristics, including quality, stickiness, and appearance, were evaluated, and its pharmacokinetics and irritation to the skin were evaluated by applying it to rabbits and rats. The optimal formulation of the CTH TDDS was 49.2% hydroxypropyl methyl cellulose K100M, 32.8% polyvinylpyrrolidone K30, 16% oleic acid-azone, and 2% polyacrylic acid resin II. The system continuously released an effective dose of CTH for 24 h and significantly enhanced its bioavailability, with a higher area under the curve, good stability, and no skin irritation. The developed CTH TDDS possessed a sustained-release effect and good characteristics and pharmacokinetics; therefore, it has the potential for clinical application as an antidepressant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin AbsorptionCitalopramRatsRabbitsAnimalsDelayed-Action PreparationsAdministration, CutaneousSkinDrug Delivery SystemsTransdermal Patch

Stichwörter der Autor:innen

citalopram hydrobromidepharmacokineticsskin irritationtransdermal delivery

Substanzen

CitalopramDelayed-Action Preparations

Autor:innen und Institutionen

  • College of Life Sciences, Nankai University, Tianjin 300071, China.
  • Harvest Pharmaceutical Co., Ltd., Changsha 410000, China.

ORCID-Profile: Yan-Qiang Liu

Förderung

  • Natural Science Foundation of Tianjin City
  • Fundamental Research Funds for the Central Universities of Nankai University
  • University–Enterprise Cooperation Project

Zitieren

APA

Sun, Y. Y., Ni, Y. J., Wang, R. J., Qin, Z. C., Liu, Z., Xiao, L. H., & Liu, Y. Q. (2024). Establishment and Validation of a Transdermal Drug Delivery System for the Anti-Depressant Drug Citalopram Hydrobromide. Molecules, 29(4), 767. https://doi.org/10.3390/molecules29040767

Vancouver

Sun YY, Ni YJ, Wang RJ, Qin ZC, Liu Z, Xiao LH, et al. Establishment and Validation of a Transdermal Drug Delivery System for the Anti-Depressant Drug Citalopram Hydrobromide. Molecules. 2024;29(4):767. doi:10.3390/molecules29040767

BibTeX
@article{Sun2024,
  author = {Sun, Yi-Yang and Ni, Ya-Jing and Wang, Run-Jia and Qin, Zi-Cheng and Liu, Zhao and Xiao, Li-Hui and Liu, Yan-Qiang},
  title = {Establishment and Validation of a Transdermal Drug Delivery System for the Anti-Depressant Drug Citalopram Hydrobromide},
  journal = {Molecules},
  year = {2024},
  volume = {29},
  number = {4},
  pages = {767},
  doi = {10.3390/molecules29040767}
}
Kostenlos starten →